RESCRIPTOR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESCRIPTOR is an oral small-molecule antiviral tablet approved in 1997 by GSK. The specific indication and mechanism of action are not documented in available data. This product is in the late stage of its commercial lifecycle with loss of exclusivity approaching.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) suggests team focus is transitioning from growth to retention and lifecycle management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Started Dec 2003
3 enrolled
HIV-1 Infection
Career Relevance
RESCRIPTOR currently has zero active job postings linked to it, reflecting its mature lifecycle stage. Opportunities for new hires are limited; existing roles focus on protecting market share through pricing, reimbursement, and generic defense strategies.
Brand Manager
Worked on RESCRIPTOR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.